Home › Companies › RARE

Ultragenyx Pharmaceutical

Market cap $1.70B 101.9M shares (10-Q, Oct 29, 2026) × $16.70 close Nov 17, 2026

Most recent annual filing: 2026-02-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. UX016 Ph1 start2H 2026UX016 Ph1 start, 2H 2026, routine
  2. DTX301 OTC topline1H 2027DTX301 OTC topline, 1H 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

Discontinued (2)

Capital (as filed)

Cash
$150M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$116M Sep 30, 2026
Long-term investments
$135M Sep 30, 2026
Operating cash flow
−$43.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$401M cash per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (16)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (16 calls)

Every verdict Biotech Distilled has published on Ultragenyx Pharmaceutical, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Ultragenyx Pharmaceuticals (RARE): Scientific Deep Dive for Lead and Pipeline Products Cash burn is too high relative to immediate revenue growth and CMC/manufacturing risk at Bedford is too elevated to justify a long position ahead of the gene therapy PDUFA dates.
  2. Watch Update: Ultragenyx (RARE) - Q4 2025 Report Layoffs bridge the dilution gap but margin for error is zero; waiting for Q3 PDUFA clearances before taking a position remains the right call.
  3. Watch UPDATE: Ultragenyx (RARE) - 10-K Autopsy: Suing the CDMO and Mortgaging the Crown Jewels Catalent lawsuit and Bedford facility history make manufacturing risks too glaring to take a long position ahead of FDA facility inspections.
  4. Watch UPDATE: Ultragenyx (RARE) - A Date With Destiny DTX401 clinical risk dropped with no AdCom, but manufacturing risk remains Code Red due to Catalent litigation and prior UX111 CRL; keeping powder dry until FDA facility inspection updates.
  5. Watch UPDATE: Ultragenyx (RARE) - The Science Delivers (Again), But the Factory Remains the Boss DTX301 Phase 3 win raises sum-of-parts value but CMC-driven CRL risk in August remains the binding constraint; staying on sidelines until Bedford is cleared.
  6. Watch UPDATE: Ultragenyx (RARE) - Both PDUFA Dates Are Now on the Calendar Two hard PDUFA dates set but manufacturing risk unchanged at Code Red; 13% run-up since March eats into margin of safety without new CMC data.
  7. Watch UPDATE: Ultragenyx (RARE) - The Angelman Safety Signal Just Got Quieter, and the Cash Got Lighter GTX-102 safety risk improved meaningfully with 3-year clean LTE data but manufacturing risk stays Code Red and cash burn tightened; gating event remains August 23 DTX401 PDUFA.
  8. Watch speculative UPDATE: Ultragenyx (RARE) - The Burn Rate Just Halved, and the Angelman Clock Got a Month Halved burn rate, record revenue, and extended runway shift the asymmetry enough to move off pure sidelines, but manufacturing risk stays Code Red; pre-PDUFA weakness may offer a better entry than waiting for confirmation.
  9. Speculative buy speculative UPDATE: Ultragenyx (RARE) - One of My Three Sell Triggers Just Got Defused Esjay Dojolvi settlement pushes generic entry to 2033, removing one of three sell triggers and improving the commercial floor, but manufacturing risk stays Code Red twelve days from the PDUFA.
  10. Buy core UPDATE: Ultragenyx (RARE) - Bedford Passed FDA approved GENGLYCOS manufactured entirely at Bedford, retiring the existential CMC risk; with UX111 PDUFA and Angelman readout still ahead, building a position before the second and third cards flip is now justified.
  11. Hold UPDATE: Ultragenyx (RARE) - The Crown Jewel Broke Phase 3 Aspire missed primary and all five MDRI components with zero separation, eliminating the Angelman rerating thesis; remaining commercial base, approved gene therapy, and September 19 UX111 PDUFA are intact but no longer justify a premium multiple.
  12. Buy core UPDATE: Ultragenyx (RARE) - The Last Card Flipped, and It Was Better Than the Deck Promised FAYUVI received full standard approval (not accelerated) with 23.5-point cognitive separation at p<0.0001, Bedford cleared twice in 30 days, two PRVs in hand, and the stock is 45% below pre-Aspire levels — two approved gene therapies and a growing commercial base now available at a significant discount.
  13. Buy core UPDATE: Ultragenyx (RARE) - The Voucher Cashed at Double GENGLYCOS PRV sold for $210M (~$168M net), roughly double the modeled ~$100M, closing the dilution gap with non-dilutive cash; second PRV still available.
  14. Buy core UPDATE: Ultragenyx (RARE) - Two Vouchers, One Shrug Second PRV sold for $203M, bringing combined net voucher proceeds to ~$371M — nearly double the modeled amount — without diluting shareholders; balance sheet close to half the market cap.
  15. Buy core UPDATE: Ultragenyx (RARE) - The Mall Closes a Wing 20% layoff, wind-down of Angelman and UX701, and ~$350M net voucher cash transform RARE into a leaner commercial company with two approved gene therapies and a balance sheet near 45% of market cap.
  16. Buy core UPDATE: Ultragenyx (RARE) - The 10-Q Fine Print 10-Q reveals 2027 gene therapy revenue relies on fragile ex-US named-patient sales and margins flattered by pre-expensed inventory, but ~$750M pro-forma cash and two Bedford-approved gene therapies keep the floor intact.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (37)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

15 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)